EIK-1001

Isomorphic Labs raised $600 million in its first external funding round in March 2025, representing the largest private biotech investment of the month.

Eikon Therapeutics has successfully raised $350.7 million in Series D funding, bringing their total funding to over $1.1 billion since 2019, with potential for additional investors to join later this year.

Clinical trials are becoming increasingly complex and expensive as they target smaller patient populations and face stricter regulations, driving the need for smarter and more efficient trial designs.